Cargando…

Modeling the influence of stromal microenvironment in the selection of ENU-induced BCR-ABL1 mutants by tyrosine kinase inhibitors

Tyrosine kinase inhibitors (TKIs) have profoundly changed the natural history of chronic myeloid leukemia (CML). However, acquired resistance to imatinib, dasatinib or nilotinib (1(st) and 2(nd) generation TKIs), due in part to BCR-ABL1 kinase mutations, has been largely described. These drugs are i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aggoune, Djamel, Tosca, Lucie, Sorel, Nathalie, Bonnet, Marie-Laure, Dkhissi, Fatima, Tachdjian, Gérard, Bennaceur-Griscelli, Annelise, Chomel, Jean-Claude, Turhan, Ali G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295758/ https://www.ncbi.nlm.nih.gov/pubmed/25593988

Ejemplares similares

ENOX2 NADH Oxidase: A BCR-ABL1-Dependent Cell Surface and Secreted Redox Protein in Chronic Myeloid Leukemia
por: Baykal, Seda, et al.
Publicado: (2023)

Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with BCR::ABL1 from Chronic Myeloid Leukemia (CML) in Blast Crisis
por: Boucher, Lara, et al.
Publicado: (2023)

Genomic instability of human embryonic stem cell lines using different passaging culture methods
por: Tosca, Lucie, et al.
Publicado: (2015)

Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation
por: Chomel, Jean Claude, et al.
Publicado: (2016)

iPSC-Derived Hereditary Breast Cancer Model Reveals the BRCA1-Deleted Tumor Niche as a New Culprit in Disease Progression
por: Portier, Lucie, et al.
Publicado: (2021)

Genomic landscape analyses of reprogrammed cells using integrative and non-integrative methods reveal variable cancer-associated alterations
por: Griscelli, Frank, et al.
Publicado: (2019)

PPARγ Cistrome Repression during Activation of Lung Monocyte-Macrophages in Severe COVID-19
por: Desterke, Christophe, et al.
Publicado: (2020)

HLA-dependent heterogeneity and macrophage immunoproteasome activation during lung COVID-19 disease
por: Desterke, Christophe, et al.
Publicado: (2021)

EGR1 dysregulation defines an inflammatory and leukemic program in cell trajectory of human-aged hematopoietic stem cells (HSC)
por: Desterke, Christophe, et al.
Publicado: (2021)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

Bcr-Abl tyrosine kinase inhibitors- current status
por: Mughal, Anum, et al.
Publicado: (2013)

Global MicroRNA Profiling Uncovers miR-206 as a Negative Regulator of Hematopoietic Commitment in Human Pluripotent Stem Cells
por: Flamant, Stéphane, et al.
Publicado: (2019)

Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation
por: Deutsch, E, et al.
Publicado: (2004)

Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
por: Carofiglio, Francesca, et al.
Publicado: (2020)

Case report: Long-term voluntary Tyrosine Kinase Inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML): Molecular evidence of an immune surveillance
por: Imeri, Jusuf, et al.
Publicado: (2023)

Modeling Blast Crisis Using Mutagenized Chronic Myeloid Leukemia-Derived Induced Pluripotent Stem Cells (iPSCs)
por: Imeri, Jusuf, et al.
Publicado: (2023)

Detection of Hematopoietic Stem Cell Transcriptome in Human Fetal Kidneys and Kidney Organoids Derived From Human Induced Pluripotent Stem Cells
por: Hwang, Jin Wook, et al.
Publicado: (2021)

Identification of Spectral Modifications Occurring during Reprogramming of Somatic Cells
por: Sandt, Christophe, et al.
Publicado: (2012)

Embryonic Program Activated during Blast Crisis of Chronic Myelogenous Leukemia (CML) Implicates a TCF7L2 and MYC Cooperative Chromatin Binding
por: Desterke, Christophe, et al.
Publicado: (2020)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases
por: La Spina, Enrico, et al.
Publicado: (2023)

Molecular investigation of adequate sources of mesenchymal stem cells for cell therapy of COVID‐19‐associated organ failure
por: Desterke, Christophe, et al.
Publicado: (2020)

Evidence of Antitumor and Antimetastatic Potential of Induced Pluripotent Stem Cell-Based Vaccines in Cancer Immunotherapy
por: Kishi, Masae, et al.
Publicado: (2021)

Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
por: Takeuchi, Asako, et al.
Publicado: (2020)

iPSC-Derived Organoids as Therapeutic Models in Regenerative Medicine and Oncology
por: Turhan, Ali G., et al.
Publicado: (2021)

Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders
por: Mesa, Ruben A
Publicado: (2007)

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
por: Cuellar, Sandra, et al.
Publicado: (2017)

Combination of Bortezomib and Mitotic Inhibitors Down-Modulate Bcr-Abl and Efficiently Eliminates Tyrosine-Kinase Inhibitor Sensitive and Resistant Bcr-Abl-Positive Leukemic Cells
por: Bucur, Octavian, et al.
Publicado: (2013)

Tyrosine kinase inhibitors induce alternative spliced BCR‐ABL (Ins35bp) variant via inhibition of RNA polymerase II on genomic BCR‐ABL
por: Yuda, Junichiro, et al.
Publicado: (2020)

Clinically silent indolent T‐cell leukemia
por: Janot, Clément, et al.
Publicado: (2018)

Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia
por: de Almeida, Maria Helena, et al.
Publicado: (2014)

Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase
por: Reckel, Sina, et al.
Publicado: (2017)

BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
por: Haguet, Hélène, et al.
Publicado: (2018)

BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon
por: Stanchina, Michele, et al.
Publicado: (2020)

BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
por: Kauer, Joseph, et al.
Publicado: (2022)

A mesenchymal glioma stem cell profile is related to clinical outcome
por: Balbous, A, et al.
Publicado: (2014)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Patient-Derived iPSCs Reveal Evidence of Telomere Instability and DNA Repair Deficiency in Coats Plus Syndrome
por: Oudrhiri, Noufissa, et al.
Publicado: (2022)

NS-187 (INNO-406), a Bcr-Abl/Lyn Dual Tyrosine Kinase Inhibitor
por: Niwa, Tomoko, et al.
Publicado: (2007)

Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia
por: Boer, Judith M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0tl5k45367uuop8bjl2ri8anjs